ARTHArch Therapeutics, Inc.

About Arch Therapeutics, Inc. (ARTH)

Arch Therapeutics, Inc. (ARTH) is a Biotechnology company headquartered in Framingham, MA, United States whose shares trade over-the-counter on the Expert Market tier.

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's products authorized for commercial marketing are AC5 Advanced Wound System and AC5 Topical Hemostat. Arch's development stage product candidates include AC5-GTM and AC5 Surgical Hemostat, among others.

Products and services

Our flagship products and product candidates are derived from our AC5 self-assembling peptide (SAP) technology platform and are sometimes referred to as AC5 or the “AC5 Devices.” These include AC5 Advanced Wound System and AC5 Topical Hemostat, which have received marketing authorization as medical devices in the United States and Europe, respectively, and which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include, for example, AC5-GTM for gastrointestinal endoscopic procedures and AC5-V® and AC5 Surgical Hemostat for hemostasis inside the body, all of which are currently investigational devices limited by law to investigational use.

ARTH key facts

Ticker symbol

ARTH

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

Framingham, MA, United States

Country of incorporation

US

Year of incorporation

2009

Employees

6

Estimated market cap

$888.9K (as of Apr 16, 2025)

Shares outstanding

4,444,363

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

9/30

Latest filing

8K Report (Feb 3, 2025)

Arch Therapeutics, Inc. leadership

• Terrence W. Norchi — President, CEO, Secretary

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with A